Spyre Therapeutics (SYRE) Gains from Investment Securities (2015 - 2024)
Spyre Therapeutics (SYRE) reported Gains from Investment Securities of -$200000.0 for Q2 2024, down 100.32% on a YoY basis from $63.4 million in Q3 2023, and up 78.0% quarter-over-quarter from -$909000.0 in Q3 2023.
Spyre Therapeutics (SYRE) Gains from Investment Securities (2015 - 2024) Analysis & Trends
Spyre Therapeutics has reported Gains from Investment Securities for 10 years, with the latest figure at -$200000.0 in Q2 2024.
- For the quarter ending Q2 2024, Gains from Investment Securities fell 100.32% year-over-year to -$200000.0; the trailing twelve-month figure through Dec 2024 stood at -$200000.0 (down 29.87% YoY), and the FY2023 full-year result was -$915000.0, down 109.04% from the prior year.
- Gains from Investment Securities for Q2 2024 stood at -$200000.0, up from -$909000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $63.4 million in Q2 2023, with the low at -$909000.0 in Q3 2023.
- Historically, Gains from Investment Securities has averaged $4.9 million across 5 years, with a median of $407100.0 in 2021.
- Annual changes were most pronounced in 2021 — Gains from Investment Securities surged 23727.14% — and 2023, when it plunged 123.66%.
- Spyre Therapeutics' Gains from Investment Securities stood at -$14000.0 in 2020, then soared by 2507.14% to $337000.0 in 2021, then increased by 24.04% to $418000.0 in 2022, then slumped by 317.46% to -$909000.0 in 2023, then soared by 78.0% to -$200000.0 in 2024.
- The last three Gains from Investment Securities figures came in at -$200000.0 (Q2 2024), -$909000.0 (Q3 2023), and $63.4 million (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Spyre Therapeutics | 6.95 Bn | 6.95 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -200,000.00 |
| Jun 30, 2024 | -200,000.00 |
| Sep 30, 2023 | -909,000.00 |
| Sep 30, 2023 | -909,000.00 |
| Jun 30, 2023 | 63.42 Mn |
| Jun 30, 2023 | 63.42 Mn |
| Mar 31, 2023 | 4.44 Mn |
| Mar 31, 2023 | 4.44 Mn |
| Dec 31, 2022 | 418,000.00 |
| Dec 31, 2022 | 418,000.00 |
| Sep 30, 2022 | 3.84 Mn |
| Sep 30, 2022 | 3.84 Mn |
| Jun 30, 2022 | 429,000.00 |
| Jun 30, 2022 | 429,000.00 |
| Mar 31, 2022 | 2.14 Mn |
| Mar 31, 2022 | 2.14 Mn |
| Dec 31, 2021 | 337,000.00 |
| Dec 31, 2021 | 337,000.00 |
| Sep 30, 2021 | 396,200.00 |
| Sep 30, 2021 | 396,200.00 |